Biomica Reports Positive Results from Pre-Clinical Studies in its Inflammatory Bowel Disease (IBD) Program
November 30, 2021
Earlier this year, initial positive pre-clinical results pointing to reduction of inflammation following treatment with BMC321 and BMC322, were achieved using a DSS-induced colitis mouse model. These results were presented at the 2021 Crohn’s & Colitis Congress, jointly organized by the American Crohn’s & Colitis Foundation (CCFA) and the... Read more
